PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.35 USD | +2.55% |
|
+21.87% | -16.76% |
| 04-15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| 04-12 | Pharvaris Files Mixed Shelf | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.18B 1.26B 101B |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -123M -9.83B | Net income 2025 * | -136M -146M -11.63B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 302M 24.08B | Net cash position 2025 * | 161M 173M 13.79B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.51
x | P/E ratio 2025 * |
-9.06
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | +2.55% | ||
| 1 week | +21.87% | ||
| Current month | +1.04% | ||
| 1 month | +1.04% | ||
| 3 months | -22.01% | ||
| 6 months | +31.77% | ||
| Current year | -16.76% |
1 week
19.59
25.44
1 month
17.5725.44
Current year
17.5733.00
1 year
7.9333.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 29/09/15 |
| Founder | 65 | 29/09/15 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | 11-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 29/09/15 | |
David Meeker
CHM | Chairman | 69 | 31/12/20 |
Robert Glassman
BRD | Director/Board Member | 62 | 31/12/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 23.35 | +2.55% | 85,067 |
| 25/04/24 | 22.77 | +7.15% | 82,367 |
| 24/04/24 | 21.25 | -0.19% | 34,153 |
| 23/04/24 | 21.29 | +2.01% | 88,778 |
| 22/04/24 | 20.87 | +8.92% | 50,601 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
21.87
EUR
Average target price
31.03
EUR
Spread / Average Target
+41.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.76% | 1.26B | |
| +1.51% | 42.75B | |
| +48.32% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PHVS Stock
